Semaglutide in the BNF: reading the official UK clinical reference

The common misconception: one drug, one BNF entry

Most people searching for semaglutide in the BNF expect a single clean entry. What the BNF actually presents is semaglutide structured around its individual licensed products, because the same molecule carries meaningfully different clinical profiles depending on the brand, strength and route of administration.

Ozempic (0.5mg, 1mg, 2mg weekly injection) is licensed for type 2 diabetes. Rybelsus (3mg, 7mg, 14mg daily tablet) is also licensed only for type 2 diabetes. Wegovy (the 0.25mg–2.4mg weekly injection and, as of June 2026, the oral tablet titrated up to 25mg) is licensed specifically for weight management in adults. The BNF reflects those distinctions directly, and a prescriber consulting it for weight management would look at the Wegovy entry and the NICE technology appraisal TA875 that governs NHS use, not at the diabetes sections. If you'd like to read the BNF's own clinical monograph, the BNF semaglutide entry is publicly accessible.

This distinction is clinically important, not just administrative. The licensed dose for weight management reaches 2.4mg weekly; the diabetes doses sit below that, and you can see how those doses are structured by reading about semaglutide 1mg, which covers the clinical profile at that particular strength. Prescribing a diabetes-licensed product off-label for weight loss (or vice versa) is a different clinical act than following the licensed pathway, and the BNF's structure reinforces that boundary.

What the BNF monograph actually records for weight management

For Wegovy, the BNF monograph covers the licensed indication, the dose escalation schedule, cautions, contraindications, interactions, side effects classified by frequency, and monitoring requirements. Prescribers also have access to the full Summary of Product Characteristics through the electronic Medicines Compendium (eMC), which sits alongside the BNF in practice.

The cautions listed include a personal or family history of medullary thyroid carcinoma, pancreatitis, and certain gastrointestinal conditions. Contraindications and drug interactions (including the effect on oral drug absorption, which is why guidance specifically addresses oral contraceptives during tirzepatide use) are set out for prescribers to work through against the patient's full medicines list. That review is exactly what happens when a prescriber reads a consultation at a service like ours.

Side effects in the BNF are grouped by frequency: very common, common, uncommon, rare and very rare. For semaglutide the very common category is dominated by gastrointestinal effects, nausea, diarrhoea, vomiting, constipation and abdominal discomfort. These typically ease after the first few weeks at each dose level, which is part of why the titration schedule exists, and our page on semaglutide 2mg explains how that higher maintenance dose fits into the broader escalation picture. Patients can read the patient-facing equivalent on the NHS semaglutide medicines page.

One quick checking habit worth knowing: the BNF online at bnf.nice.org.uk is updated monthly. If you're reading about semaglutide and want to confirm the information is current, the date of the last revision appears at the top of the monograph. Takes about thirty seconds.

NICE TA875 and what the BNF cross-references for NHS use

The BNF's weight-management semaglutide entry links to NICE technology appraisal TA875, which sets the conditions under which Wegovy can be recommended on the NHS. Those conditions include use within a specialist weight management service, a maximum treatment duration of two years on the NHS, and BMI thresholds of 35 or above with at least one weight-related condition (lower thresholds apply for some ethnic backgrounds under NICE guidance). People who don't meet those criteria, or who would rather not wait for a specialist referral, can access the medicine privately through a registered pharmacy following a clinical assessment, and our Wegovy BNF page goes into detail on how those prescribing standards apply in practice. You can read more about semaglutide for weight management and how the two routes compare.

NICE TA875 also sets a review point: if a patient hasn't lost at least 5% of body weight after six months at the maintenance dose, continuing treatment is reconsidered. The BNF reflects this through its monitoring note, flagging it as a prescriber responsibility rather than something for patients to self-manage. For context on what the clinical evidence shows about results, the STEP 1 trial published in the New England Journal of Medicine reported an average of around 15% body weight reduction over 68 weeks at 2.4mg, figures the NICE committee considered when drawing up TA875.

Private prescribing and the BNF: the same standard applies

A question our prescribers hear regularly is whether private prescriptions follow the same clinical reference as NHS ones. The answer is yes. The BNF is not an NHS-only tool; it is the standard clinical reference for UK prescribers regardless of the setting, and a GPhC-registered Independent Prescriber working privately applies the same monograph, the same caution list and the same interaction checks as their NHS counterpart.

At nume, every consultation is read by a named prescriber, and the clinical framework they work within reflects exactly the BNF and SmPC standards described above. If you're weighing up whether Wegovy might be clinically suitable for you, or comparing it with other licensed options, our weight loss treatment overview sets out what's available. For a sense of what treatment typically costs privately, the Wegovy cost page covers the context without any surprises.

When you're ready to find out whether semaglutide is right for your situation, start your free consultation and a prescriber will review your answers the same day.